Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by NewToInvesting7on Sep 22, 2020 2:55pm
92 Views
Post# 31598395

RE:RE:Timeframe

RE:RE:TimeframeI actually hope that we do not get a NR until after the Q3 results are anounced.  Personally, I hope that by reporting the Q3 numbers, we will see a jump in the stock price to reflect the company performance.  Then, by releasing the NRs after this, the jump in the stock price would likely be higher than if there were NRs followed by Q3 reporting.

Just my 2 cents anyway.  I am not an analyst and am not versed in stocks or what affects their performance.    



ompong12 wrote: I don't think so....Tripp is bound to release any material info in a timely manner as it occurs.

JACKTHEBEAR2 wrote: I would think the timetable set for a release is somewhere after the two weeks following the consolidation to allow time for all things to settle in accounts. That would put first week of Oct as earliest moment to see news.




<< Previous
Bullboard Posts
Next >>